Why suddenly people from all over the world including India are buying shares of Hyderabad based company Dr Reddy’s?

New Delhi. Pharma company Dr Reddy’s has been in the news continuously for the last two days. Earlier there were discussions about the company because of the agreement regarding Russia’s Corona Vaccine. At the same time, now talks are going on regarding the shares of the company. On Friday, it increased by 10 percent to reach Rs 5300. The company’s shares have touched this level for the first time. Today, with a rise of 10 percent, the market cap of Dr. Reddy’s reached close to Rs 88110 crore. Whereas yesterday the market cap of the company was Rs 80239 crore. At the same time, in 6 months the wealth of investors increased from Rs 41521 crore to Rs 88109 crore i.e. more than doubled. Experts say that Dr. Reddy’s has settled the patent dispute related to cancer drug Revlimid with Celgene. The company will now be able to sell this medicine in America after March 2022. After this news the stock has increased.

Investors from all over the world are buying Dr. Reddy’s shares vigorously. Dr Reddy’s shares fell in a week It has given bumper returns of 21%, 18% in one month, 91% in six months and 95% in one year.

Also read- Important news for 40 crore customers of SBI! Bank changed 4 rules

What should investors do now? The world’s largest rating agency Credit Suisse has given outperform rating on Dr. Reddy’s and has increased the target from Rs 5100 to Rs 5750. Cash flow of up to $700 million is possible from Revlimid generic. It is one of the two companies selling Avigan in the US. The company can increase its market share in Suboxone.

At the same time, American Bank Citi has said in its report that Revlimid can be launched in the US after March 2022. This will be the third settlement for Revlimid after Natco, Alvogen.

A big agreement has been made regarding Corona vaccine – The Russian Direct Investment Fund (RDIF) will work with Dr. Reddy’s Laboratories for testing and distribution of its vaccine Sputnik-5 against Covid-19 in India.

RDIF Chief Executive Officer Kirill Dmitriev gave this information on Wednesday. He said that RDIF is in talks with Indian regulators to ensure that all the necessary conditions are met for clinical trials of the vaccine.

Dmitriev said in an e-mail interview to ‘PTI-Bhasha’, “An agreement has been reached between RDIF and Dr. Reddy’s Laboratories Limited, a global pharmaceutical company headquartered in India, on the supply of 100 million Russian Sputnik-5 vaccines and India. They will also work together on clinical testing and distribution of the vaccine.

Why suddenly people from all over the world including India are buying shares of Hyderabad based company Dr Reddy's?

The vaccine Sputnik-5 against Corona virus has been jointly developed by Gamaleya National Pathology and Microorganism Research Institute and RDIF. Dmitriev said that additional clinical studies of Sputnik-5 will be conducted in other countries including Brazil, India, Saudi Arabia, Egypt, United Arab Emirates and Belarus. Russia had said earlier this month that it was in touch with Indian officials on the vaccine issue.

Tags: corona vaccine, Corona vaccine news, corona virus, Coronavirus, Coronavirus in India, COVID-19 pandemic, Pharma Industry, Pharma units, Pharmaceutical company

Related articles